Vertex Pharmaceuticals Incorpor (VRTX) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Vertex Pharmaceuticals Incorpor

NasdaqGS•Healthcare•Biotechnology

$530.76-22.39(-0.04%)After hours

Market Cap

$140.33B

P/E

31.9x

P/S

11.1x

P/B

6.9x

Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

How this company scores

ExcellentMetricSide Score: 81/100

Strongest: Growth (23/25); weakest: Balance Sheet & Red Flags (15/25).

Profitability22/25

Growth23/25

Balance Sheet & Red Flags15/25

Cash & Earnings Quality21/25

Strengths

Strong marginsHigh ROERising earningsInterest easily covered

No red flags in the last 8 quarters.

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 31.9x5y range 21.6x – 31.9x

Currently near its 16-quarter median.

P/S · 11.1x5y range 6.6x – 11.7x

Currently near its 20-quarter median.

P/B · 6.9x5y range 4.9x – 8.2x

Currently near its 20-quarter median.

Price & Volume

Market Cap $140.33B

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $12.59B
Q. Revenue: $3.33B
TTM EBITDA: $5.00B
TTM Op. Income: $4.78B
Q. Op. Income: $1.25B
TTM Net Income: $4.41B
Q. Net Income: $1.10B
EPS: $4.34
Shares Out.: $253.70M

$12.59B in TTM revenue grew 10.2% YoY, reaching $3.33B last quarter. TTM EBITDA of $5.00B and TTM operating income of $4.78B show growth is flowing through to the bottom line. TTM net income of $4.41B means revenue is converting into profit. Across the last 8 quarters, TTM revenue has risen for 7 consecutive quarters — an improving trend.

Margins

Gross, EBITDA, operating, and net margin trends

EBITDA Margin: 39.1%
Op. Margin: 37.4%
Net Margin: 33.0%

Op. margin of 37.4% is down 1.4% YoY — costs are rising relative to revenue. Net margin at 33.0% Over the past year, operating margin is down 4% — a weakening trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: 31.9x
P/S Ratio: 11.1x
P/B Ratio: 6.9x

At 31.9x P/E, the stock trades above typical market levels — the market expects above-average growth. P/S of 11.1x and P/B of 6.9x provide additional context. Use the growth and margin sections to judge whether the multiple is justified. Over the past year, P/E is up 1% — a weakening trend.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $27.42B
Cash: $6.14B
Long-Term Debt: N/A
Book Value: $20.25B
D/E Ratio: N/A
Debt/EBITDA: 0.0

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $1.13B
TTM Free Cash Flow: $3.80B
FCF Margin: 30.2%
FCF / Net Income: 0.9

TTM FCF of $3.80B on $1.13B in operating cash flow. The FCF / Net Income ratio of 0.9x means free cash flow covers net income — earnings are backed by cash. Across the last 8 quarters, free cash flow has risen for 2 consecutive quarters — an improving trend.